Carlos Julian Díaz-Torres , Irina Katia Cano Flores , Julio A. Poterico
{"title":"一名霍奇金淋巴瘤患者的小儿多系统炎症综合征:病例报告","authors":"Carlos Julian Díaz-Torres , Irina Katia Cano Flores , Julio A. Poterico","doi":"10.1016/j.phoj.2024.03.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The inflammatory state of Hodgkin lymphoma can generate increases in inflammatory markers that can sometimes be attributed to an infection in these immunosuppressed patients. During the COVID-19 pandemic, the diagnosis and treatment of patients with hematological malignancies was complicated by the presence of SARS-CoV2. It could range from an asymptomatic presentation to a multisystem inflammatory syndrome known as the Pediatric inflammatory multisystem syndrome (PIMS).</p></div><div><h3>Case report</h3><p>We present the case of a girl who, during the COVID-19 pandemic, was treated at our institution for lymphadenopathy and persistent fever. The febrile syndrome was attributed to intercurrent infection; however, despite antimicrobial coverage, fever persisted, and inflammatory markers increased. Although SARS-CoV2 was not detected in the samples, PIMS was clinically suspected. Treatment with human immunoglobulin and acetylsalicylic acid was administered. An improvement in the inflammatory parameters was observed, which allowed ruling out an opportunistic infection and initiating chemotherapy.</p></div><div><h3>Conclusion</h3><p>A patient diagnosed with lymphoma and presenting with PIMS could have a synergic interaction of both conditions, resulting in an adverse outcome.</p></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"9 2","pages":"Pages 95-100"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468124524000214/pdfft?md5=fcc97a4d35714b17da085869ada28f48&pid=1-s2.0-S2468124524000214-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Pediatric inflammatory multisystem syndrome in a patient with Hodgkin lymphoma: A case report\",\"authors\":\"Carlos Julian Díaz-Torres , Irina Katia Cano Flores , Julio A. Poterico\",\"doi\":\"10.1016/j.phoj.2024.03.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The inflammatory state of Hodgkin lymphoma can generate increases in inflammatory markers that can sometimes be attributed to an infection in these immunosuppressed patients. During the COVID-19 pandemic, the diagnosis and treatment of patients with hematological malignancies was complicated by the presence of SARS-CoV2. It could range from an asymptomatic presentation to a multisystem inflammatory syndrome known as the Pediatric inflammatory multisystem syndrome (PIMS).</p></div><div><h3>Case report</h3><p>We present the case of a girl who, during the COVID-19 pandemic, was treated at our institution for lymphadenopathy and persistent fever. The febrile syndrome was attributed to intercurrent infection; however, despite antimicrobial coverage, fever persisted, and inflammatory markers increased. Although SARS-CoV2 was not detected in the samples, PIMS was clinically suspected. Treatment with human immunoglobulin and acetylsalicylic acid was administered. An improvement in the inflammatory parameters was observed, which allowed ruling out an opportunistic infection and initiating chemotherapy.</p></div><div><h3>Conclusion</h3><p>A patient diagnosed with lymphoma and presenting with PIMS could have a synergic interaction of both conditions, resulting in an adverse outcome.</p></div>\",\"PeriodicalId\":101004,\"journal\":{\"name\":\"Pediatric Hematology Oncology Journal\",\"volume\":\"9 2\",\"pages\":\"Pages 95-100\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2468124524000214/pdfft?md5=fcc97a4d35714b17da085869ada28f48&pid=1-s2.0-S2468124524000214-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Hematology Oncology Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468124524000214\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468124524000214","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pediatric inflammatory multisystem syndrome in a patient with Hodgkin lymphoma: A case report
Background
The inflammatory state of Hodgkin lymphoma can generate increases in inflammatory markers that can sometimes be attributed to an infection in these immunosuppressed patients. During the COVID-19 pandemic, the diagnosis and treatment of patients with hematological malignancies was complicated by the presence of SARS-CoV2. It could range from an asymptomatic presentation to a multisystem inflammatory syndrome known as the Pediatric inflammatory multisystem syndrome (PIMS).
Case report
We present the case of a girl who, during the COVID-19 pandemic, was treated at our institution for lymphadenopathy and persistent fever. The febrile syndrome was attributed to intercurrent infection; however, despite antimicrobial coverage, fever persisted, and inflammatory markers increased. Although SARS-CoV2 was not detected in the samples, PIMS was clinically suspected. Treatment with human immunoglobulin and acetylsalicylic acid was administered. An improvement in the inflammatory parameters was observed, which allowed ruling out an opportunistic infection and initiating chemotherapy.
Conclusion
A patient diagnosed with lymphoma and presenting with PIMS could have a synergic interaction of both conditions, resulting in an adverse outcome.